Precigen Inc Stock Price, News & Analysis

On April 26, 2023, Precigen (Nasdaq: PGEN) announced its participation in the 2023 ASCO Annual Meeting from June 2-6, 2023, in Chicago, Illinois. The company will present clinical data on two innovative therapies: PRGN-3005 UltraCAR-T for advanced, recurrent platinum-resistant ovarian cancer and PRGN-2009 AdenoVerse immunotherapy for HPV-associated cancers. Highlights include:

• PRGN-3005: Phase 1/1b study demonstrating the potential of overnight manufactured UltraCAR-T cells.
• PRGN-2009: Phase 1 study evaluating its effectiveness alone and with an anti-PDL1/TGF-Beta trap checkpoint inhibitor.

Event details and updates can be found on Precigen's investor website.

Precigen, Inc. (Nasdaq: PGEN) presented preclinical data for its next-generation UltraCAR-T platform using a mesothelin (MSLN) CAR at the AACR Annual Meeting 2023. MSLN is overexpressed in various solid tumors including mesothelioma and pancreatic cancer.

The new UltraCAR-T cells feature a novel mechanism for intrinsic PD-1 blockade, aiming to enhance safety and efficacy by eliminating the need for expensive checkpoint inhibitors. Results showed robust UltraCAR-T cell expansion and durable persistence leading to significant antitumor effects in preclinical models, even after tumor rechallenges. Collectively, these findings position the UltraCAR-T platform as a promising candidate in the cancer treatment landscape.

Precigen (NASDAQ: PGEN) has amended its license agreement with Alaunos Therapeutics, regaining exclusive rights to IL-12 gene therapy and proven CAR-T targets CD19 and BCMA. This amendment eliminates future royalties to Alaunos and enhances Precigen's ability to develop and commercialize UltraCAR-T therapies. The UltraCAR-T platform aims to deliver personalized treatments with overnight manufacturing, potentially transforming cancer therapy. The company is progressing its clinical programs for various cancers while planning a business and clinical update call on April 4, 2023.

Precigen, Inc. (NASDAQ: PGEN) announced the first patient dosing in the Phase 1/1b study of PRGN-3007, an investigational UltraCAR-T therapy targeting advanced ROR1-positive hematological and solid tumors. This innovative therapy integrates PD-1 checkpoint inhibition and aims to simplify and reduce costs associated with current treatments by eliminating the need for systemic checkpoint inhibitors. The clinical trial will enroll patients with chronic lymphocytic leukemia, mantle cell lymphoma, acute lymphoblastic leukemia, and diffuse large B-cell lymphoma. With over 100,000 patients diagnosed in the U.S., E.U., and Japan in 2023, this development marks a significant milestone for Precigen's advanced cancer therapies.

Precigen, Inc. (Nasdaq: PGEN) announced that its President and CEO, Helen Sabzevari, PhD, will join a virtual fireside chat on April 4, 2023, from 10:45 AM to 11:15 AM ET at Cantor's "The Future of Oncology" Virtual Symposium.

Specializing in innovative gene and cell therapies, Precigen aims to address urgent healthcare challenges in immuno-oncology, autoimmune disorders, and infectious diseases. Investors can find more details in the Events & Presentations section on Precigen's website.

Precigen (Nasdaq: PGEN) reported significant clinical advancements in its UltraCAR-T® and AdenoVerse™ therapies for 2022. The company presented positive results for PRGN-2012, showing a 50% complete response rate in recurrent respiratory papillomatosis, and PRGN-3006 demonstrated a 27% objective response rate in relapsed AML patients. Precigen strengthened its balance sheet through a non-health subsidiary divesture and raised approximately $73 million in a stock offering. As of December 31, 2022, it maintained $99.7 million in cash and equivalents, providing a healthy cash runway into late 2024. Total revenues increased by 89% year-over-year, but losses from continuing operations were $79.8 million.

Precigen, Inc. (Nasdaq: PGEN) has successfully closed its underwritten public offering of 42,857,143 shares of common stock at a price of $1.75 per share. The offering generated gross proceeds of approximately $75.0 million before expenses. J.P. Morgan Securities LLC and Cantor Fitzgerald & Co. were the lead managers. The offering was made under an effective shelf registration statement filed with the SEC. Precigen focuses on advancing gene and cell therapies targeting various diseases, including cancer and autoimmune disorders, emphasizing the development of affordable biotherapeutics.

Precigen, Inc. (PGEN) has announced the pricing of a public offering of 42,857,143 shares of its common stock at $1.75 per share, targeting gross proceeds of approximately $75.0 million. The underwriters have a 30-day option to purchase an additional 6,428,571 shares. The offering is expected to close on January 27, 2023, subject to customary conditions. Proceeds will fund the development of clinical and preclinical candidates and general corporate purposes. The offering is made under a shelf registration statement effective since July 2, 2020.